Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma

Oncotarget 2024 June 20 [Link] Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, Koichiro Yamakado Abstract Objectives: Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), and…

Read More

Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study

The Lancet Oncology 2024 June 4 [Link] Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen 2, Jan P van Meerbeeck Abstract Background: Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We…

Read More

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma

Thoracic Cancer 2024 June 5 [Link] Xuemei Zhang, Lele Chang, Qian Ma, Qian Zhang, Wansu Xu, Qingwei Li Abstract Background: This study aimed to investigate the effects of immune checkpoint inhibitors (ICIs) versus chemotherapy on the prognosis of real-world diffuse pleural mesothelioma patients in China. Methods: Clinical data of 90 patients with diffuse pleural mesothelioma…

Read More

Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis

Critical Reviews in Oncology and Hematology 2024 April 26 [Link] Wei Zhuang, Lihui Liu, Boyang Sun, Hua Bai, Zhijie Wang, Jianchun Duan, Rui Wan, Zixiao Ma, Jia Zhong, Jie Wang Abstract Background: Randomized controlled trials (RCTs) of systemic therapies for unresectable malignant mesothelioma have reported conflicting results. It is crucial and urgent to find optimal…

Read More

Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights

Open Respiratory Archives 2024 April 5 [Link] Rafael López-Castro, Álvaro Fuentes-Martín, Andrea Medina Del Valle, Tania García Peña, José Soro García, Leticia López González, Ángel Cilleruelo Ramos Abstract MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded…

Read More

Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights

Open Respiratory Archives 2024 April 5 [Link] Rafael López-Castro, Álvaro Fuentes-Martín, Andrea Medina Del Valle, Tania García Peña, José Soro García, Leticia López González, Ángel Cilleruelo Ramos Abstract MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded…

Read More

Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features

Clinical Cancer Research 2024 April 7 [Link] Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi Abstract Purpose: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA…

Read More

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

Cancers 2024 March 22 [Link] Karen M Yun, Lyudmila Bazhenova Abstract Malignant pleural mesothelioma (MPM) is a heterogeneous cancer composed of distinct molecular and pathologic subtypes. Unfortunately, MPM is aggressive, and current therapies for advanced, unresectable disease remain limited to cytotoxic chemotherapy and immunotherapy. Our understanding of the genomic landscape of MPM is steadily growing,…

Read More